Strategic CDMO Partner RoslinCT is a focused CDMO for Advanced Cell and Gene Therapies with cGMP capabilities and 22 processing suites across Scotland and the US, signaling strong capacity for collaborative development and scale-up projects.

Autologous and Allogeneic The company supports both autologous and allogeneic cell therapy processes, presenting opportunities to offer end-to-end development, manufacturing, and analytical services across diverse cell therapy modalities.

Global Expansion Recent facility expansion in Hopkinton, MA to add cleanroom space positions RoslinCT to handle increased demand and potential multi-regional programs, favorable for clients seeking geographically distributed manufacturing.

Advanced Tech Capabilities Experience in iPSC line development, gene editing, and demonstration of CRISPR-edited cell therapy progress (exa-cel) provides a strong differentiator for clients requiring specialized gene-editing workflows and scalable production.

Strategic Partnerships Recent collaborations with BlueRock Therapeutics and Vertex Pharmaceuticals indicate a momentum in co-development and commercialization efforts, suggesting opportunities for new alliances, co-financing, or expanded service scopes with other industry players.